A Phase I Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51 VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab for Patients With Resected Stages IIIC/IV Melanoma

Trial Profile

A Phase I Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51 VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab for Patients With Resected Stages IIIC/IV Melanoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 24 May 2017

At a glance

  • Drugs Nivolumab (Primary) ; Ipilimumab; Montanide ISA-51; Subunit vaccines
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 May 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2018.
    • 17 May 2017 Planned End Date changed from 1 Feb 2017 to 1 Feb 2018.
    • 13 Dec 2016 Planned End Date changed from 1 Feb 2017 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top